Memantine is an uncompetitive N-methyl-d-aspartate receptor antagonist and probably also has an indirect dopaminergic action at high concentrations. We describe a person with Alzheimer's disease who developed chorea and dystonia after inadvertently doubling of her daily dose by taking extended-release (XR) memantine twice daily, rather than once daily (planned dose memantine XR, 21 mg once daily), after the drug was switched from immediate release (IR, 10 mg twice daily). Memantine is rarely associated with movement disorders, but this case emphasises the need for awareness of potential problems when switching from memantine IR to XR.
- ALZHEIMER'S DISEASE
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Twitter Follow Borna Bonakdarpour at @bbonakda and Letizia Borges at @LetiziaBorges
Contributors LGB contributed to the literature search, analysis and interpretation of the case and underlying mechanisms, as well as contributed to the writing of the manuscript. BB is the patient's attending neurologist and acquired the video, contributed to analysis and interpretation of the case and underlying mechanisms and reviewed the manuscript.
Competing interests None.
Patient consent Obtained.
Provenance and peer review Not commissioned; externally peer reviewed. This paper was reviewed by David Nicholl, Birmingham, UK.
Read the full text or download the PDF:
Other content recommended for you
- Parkinson’s disease: etiopathogenesis and treatment
- Long term motor complications of levodopa: clinical features, mechanisms, and management strategies
- ▼Memantine for dementia?
- GRIN2B encephalopathy: novel findings on phenotype, variant clustering, functional consequences and treatment aspects
- Dystonia and chorea in acquired systemic disorders
- Genetics and epigenetics of Alzheimer's disease
- Movement disorders in catatonia
- Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatment
- Sleep disturbance in movement disorders: insights, treatments and challenges
- Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease